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Abstract
Pancreatic cancer is a highly aggressive tumour that is 
very resistant to treatments and it is rarely diagnosed 
early because of absence of specific symptoms. There-
fore, the prognosis for this disease is very poor and 
it has the grim supremacy in terms of unfavourable 
survival rates. There have been great advances in sur-
vival rates for many types of cancers over the past few 
decades but hardly any change for pancreatic cancer. 
Mutations of the Ras oncogene are the most frequent 
oncogenic alterations in human cancers. The frequen-
cy of KRAS  mutations in pancreatic cancer is around 
90%. Given the well-established role of KRAS in cancer 
it is not surprising that it is one of the most attractive 
targets for cancer therapy. Nevertheless, during the 
last thirty years all attempts to target directly KRAS 
protein have failed. Therefore, it is crucial to identify 
downstream KRAS effectors in order to develop specif-
ic drugs able to counteract activation of this pathway. 
Among the different signalling pathways activated by 
oncogenic KRAS, the phosphoinositide 3-Kinase (PI3K) 
pathway is emerging as one of the most critical KRAS 
effector. In turn, PI3K activates several parallel path-
ways making the identification of the precise effectors 
activated by KRAS/PI3K more difficult. Recent data 
identify 3-phosphoinositide-dependent protein kinase 
1 as a key tumour-initiating event downstream KRAS 
interaction with PI3K in pancreatic cancer.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Recent evidence suggests that protein kinase 
1 (PDK1) is a key oncogenic driver in pancreatic can-
cer. Furthermore, PDK1 appears to be activated down-
stream the main pancreatic cancer oncogene KRAS that 
is mutated in nearly all pancreatic adenocarcinomas. 
This evidence suggests that PDK1 could represent a 
novel target in the treatment of pancreatic cancer.
Ferro R, Falasca M. Emerging role of the KRAS-PDK1 axis in 
pancreatic cancer. World J Gastroenterol 2014; 20(31): 10752-10757 
Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/
i31/10752.htm  DOI: http://dx.doi.org/10.3748/wjg.v20.i31.10752
INTRODUCTION
Pancreatic cancer is a deadly disease both because it is 
generally discovered very late but also because it is very 
resistant to chemotherapy and radiation therapy[1]. In ad-
dition, pancreatic cancer metastasizes very early and re-
cent data suggest that many patients are likely to harbour 
metastases at the time of  diagnosis[2]. The most common 
form of  pancreatic cancer occurs in the exocrine cells of  
the pancreas[3]. The exocrine pancreatic tumours account 
for over 95% of  all pancreatic cancers, and can occur 
anywhere in the pancreas, although most often they are 
found in the head of  the pancreas. Pancreatic ductal ad-
enocarcinoma (PDAC) is the most common type, repre-
senting almost 90% of  all exocrine tumours.
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PDACs develop from cells lining the ducts that carry 
the digestive juices into the main pancreatic duct and 
then on into the duodenum. Like other solid tumours, 
pancreatic cancer is the result of  a multistep process. 
Its initiation and development involves specific genetic 
changes enabling growth and survival mechanisms, ini-
tiation of  a marked desmoplastic reaction and finally 
tissue invasion and metastasis[4]. The signalling pathways 
regulating tumourigenesis are the result of  multiple in-
teractions between the pancreatic cells themselves, the 
supporting stroma and the immune system[5].
A careful molecular and pathological analysis of  evolv-
ing PDAC has revealed a characteristic pattern of  histolog-
ically defined precursors, named pancreatic intraepithelial 
neoplasia (PanIN), that has been excellently modelled 
by Hruban and colleagues[6]. In brief, the morphology 
of  the tumour progresses in steps from normal ducts 
consisting of  normal pancreatic duct cells to aberrant 
ducts with disorganised cell formations and differen-
tiation grade, and finally to infiltrating cancer. These 
morphological changes occur along with several genetic 
lesions. A comprehensive genome analysis of  24 human 
pancreatic cancers revealed an average of  63 genetic 
alterations[7]. These alterations, mainly point mutations, 
affect distinct cellular pathways that can be classified in 
12 distinct signalling pathways or processes: apoptosis, 
control of  G1/S phase transition, Hedgehog signalling, 
KRAS signalling, TGF-beta signalling, Wnt/Notch sig-
nalling, DNA damage control, homophilic cell adhesion, 
Integrin signalling, JNK signalling, Invasion and small 
GTPase signalling (other than KRAS). The first six of  
these core pathways/processes were found to be geneti-
cally altered in all the analysed samples and the last six 
were altered in 16-23 of  the 24 samples[7]. A recent com-
prehensive evaluation of  the pancreatic cancer genome 
has revealed a multitude of  additional mutated genes 
involved in chromatin modification and genes associated 
with embryonic regulation of  axon guidance[1].
The progression from normal duct epithelium to 
infiltrating PDAC involves a series of  genetic alterations 
in conjunction with morphological changes. Activating 
KRAS mutation and overexpression of  ERBB2 occur 
early in the progression (PanIN-1), inactivation of  the 
cyclin-dependent kinase inhibitor 2A at an intermediate 
stage (PanIN-2) and inactivation of  TP53, SMAD4 and 
BRCA2 occur at a late stage (PanIN-3)[1,7].
Activating KRAS mutations are the first genetic chang-
es that are detected in the progression from PanIN-1 to 
PanIN-3, even though sporadic mutation can be found 
in histologically normal pancreas and in lesions that show 
the earliest stages of  histological alterations. With disease 
progression, the prevalence of  KRAS mutation increases 
and occurs in over 90% of  PDACs[1,8-10]. Understandably, 
KRAS-dependent pathways represent the main target 
in strategies attempting to counteract pancreatic cancer 
progression. In this review we will discuss the evidence 
suggesting that targeting the phosphoinositide 3-kinase 
(PI3K)/3-phosphoinositide-dependent protein kinase 
1 (PDK1) pathway can be a valid strategy to counteract 
KRAS signalling in pancreatic cancer.
KRAS
The small GTPase KRAS is frequently mutated in hu-
man cancers, with mutations occurring in nearly all tu-
mours. Activating KRAS mutations involve only specific 
amino acids which interfere with the GTPase activity. 
Most mutations in pancreatic cancer change a glycine 
at amino acid 12 to a valine or aspartate (KRASG12V and 
KRASG12D respectively) and have a well-established role 
in the initiation and progression of  PDAC[11,12]. The 
KRAS mutation result in a constitutively active protein 
that promotes persistent signalling to downstream ef-
fectors[13]. In turn, this hyperactivated signalling results 
in enhanced stimulation of  proliferative pathways, thus 
conferring a growth advantage to the cancer cell. Several 
genetic studies have shown that activating KRAS muta-
tions are necessary for the onset of  pancreatic cancer[14]. 
An inducible pancreas-specific expression system was 
used recently to show that KRASG12D expression is also 
required for tumour maintenance[15]. In addition to can-
cer, KRAS mutations have also been identified in benign 
conditions such as chronic pancreatitis which result in 
increased risk of  developing PDAC[16]. KRAS signals via 
a number of  downstream effectors, amongst others RAF 
kinase, PI3K, guanine exchange factors for the small 
GTPases RAL (RAL-GEFs) and phospholipase Cε. In 
PDAC the main signalling pathways downstream of  
KRAS are the PI3K pathway and the mitogen-activated 
protein kinase (MAPK) cascade. Studies in pancreatic 
duct epithelial cell systems have demonstrated that the 
transforming potential of  oncogenic KRAS is dependent 
on PI3K signalling and mutated KRAS is associated with 
up-regulation of  survival signals including the PI3K/Akt 
survival pathway[17]. Knock-down of  KRAS in pancreatic 
cancer cells demonstrated reduced activation of  several 
proteins including Akt and ERK, indicating a key role 
for KRAS in regulation of  the PI3K signalling pathway 
and the MAPK signalling cascade. Members of  the 
MAPK network are rarely genetically modified in pan-
creatic cancer but this signalling pathway can be hyper-
activated by constitutively active KRAS. Indeed targeting 
the RAF/MEK/ERK pathway in the MAPK cascade 
with selective drugs has shown promising effects on 
pancreatic cancer growth. The MAPK cascade and the 
PI3K pathway are both classically activated via Receptor 
Tyrosine Kinases like the epidermal growth factor recep-
tors (EGFR). Since EGFR gene (ERBB2) amplification 
is one of  the early genetic events in the development of  
pancreatic neoplasia these pathways can be further acti-
vated through EGFR in pancreatic cancer[18].
PI3K PATHWAY
The PI3K pathway is involved in inhibition of  apoptosis 
and stimulation of  cell proliferation and it has been esti-
mated that at least 50% of  all cancer types are related to 
deregulation of  this signalling pathway[19]. Of  the 8 mam-
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malian PI3K isoforms gain of  PIK3CA (PI3K/p110α) 
function by mutation is common in several human can-
cers[20,21]. On the other hand we have recently shown that 
the PI3K isoform p110γ is specifically overexpressed in 
PDAC[22]. Upon activation PI3Ks catalyse the phosphory-
lation of  phosphoinoisitides promoting recruitment of  
downstream signalling molecules such as Akt and PDK1 
to the plasma membrane which in turn induce several 
physiological functions such as cell growth, cell survival, 
cell migration, and cell cycle entry[23]. This activation is 
negatively regulated by the tumour suppressor phospha-
tase and tensin homolog (PTEN)[24]. PTEN mutations 
are rare in human PDAC, but loss of  PTEN function has 
been shown to be involved in pancreatic cancer result-
ing in sustained PI3K activation[25]. Furthermore, animal 
models with KRASG12D activation and PTEN deletion de-
velop pancreatic cancer with an accelerated phenotype of  
acinar-to-ductal metaplasia, leading to PanIN and cancer 
progression[26].
Increased activation of  the PI3K effector Akt was 
shown to be a common feature and a biological indicator 
of  aggressiveness in PDAC[27,28]. Additionally, it has been 
reported that Akt is a regulator of  cell plasticity in the 
pancreas. Indeed it has been shown that constitutively ac-
tive Akt induced expansion of  the ductal compartment, 
and also led to premalignant lesions in vivo[29].
PI3K signalling in the microenvironment has further 
been demonstrated to enhance tumour progression. 
Specifically, blocking PI3K/p110γ expressed by my-
eloid cells in the stroma significantly suppresses tumour 
growth and invasion[30].
KRAS/PI3K/PDK1 AXIS
It has been recently shown that PDK1 is required for 
anchorage-independent and xenograft growth of  breast 
cancer cells harbouring either PI3KCA or KRAS muta-
tions[31]. The most compelling evidence for the existence 
of  a KRAS/PI3K/PDK1 axis derives from a recent 
study demonstrating that PI3K-PDK1 signalling is an 
essential node of  non-oncogene addiction in KRAS-
driven pancreatic cancer initiation and maintenance[32].
Indeed, using genetic and pharmacological approaches 
KRAS/PI3K/PDK1 axis has been shown to be an es-
sential pathway for pancreatic cancer being able to induce 
cell plasticity, acinar-to-ductal metaplasia, intraepithelial 
neoplasia, and pancreatic cancer formation as well as 
tumour maintenance. Interestingly, the authors further 
showed that ablation of  PDK1 specifically in the epithe-
lial compartment of  the lung using two different recom-
bination strategies, had no significant inhibitory effect 
on KRASG12D-induced Non-small-cell lung carcinoma 
(NSCLC) development and progression, supporting the 
conclusion that PDK1 might have a specific role down-
stream of  KRAS in pancreatic cancer. Nevertheless, 
more evidence is required to conclude that PDK1 has a 
specific role downstream of  KRAS in pancreatic cancer.
On the other hand, this demonstrates that there are 
substantial tissue- and context-specific differences in ac-
tivation of  KRAS effectors. Such differences may have 
important clinical implications because they could explain 
the diverse response to targeted therapies of  different 
tumour types harbouring oncogenic KRAS mutations. 
Indeed, a recent study showed no substantial response of  
KRASG12D-driven NSCLC toward PI3K-mTOR inhibi-
tion in vivo[33]. We have recently reported that the PDK1-
specific inhibitor 2-O-benzyl-myo-inositol 1,3,4,5,6-pen-
takisphosphate (2-O-Bn-IP5), strongly reduced the num-
ber of  surviving pancreatic cancer cells in vitro[34]. Our 
data further revealed that 2-O-Bn-IP5 is able to sensitise 
cancer cells, including pancreatic cancer cells, to the pro-
apoptotic effect of  anti-cancer drugs. Our data thus 
provide further evidence for the rationale to investigate 
KRAS-driven oncogenic pathways in a tissue- and con-
text-specific manner to characterize the relevant nodes 
engaged in different tumour entities.
Interestingly, recent work has revealed that PDK1 
directly phosphorylates the Polo-like kinase 1 (PLK1) 
which in turn induces MYC phosphorylation[35]. This novel 
PDK1-PLK1-MYC signalling regulates cancer cell growth 
and survival. In addition, it has been shown that MYC 
controls generation of  self-renewing metastatic pancre-
atic cancer cells[36]. Indeed stable expression of  activated 
KRASG12D confers a large degree of  phenotypic plasticity 
to cells that predisposes them to neoplastic transforma-
tion and acquisition of  stem cell characteristics. Ischenko 
et al[36] demonstrated that metastatic conversion of  KRAS-
G12D-expressing cells, that exhibit different degrees of  dif-
ferentiation and malignancy, can be reconstructed in cell 
culture, and that the proto-oncogene c-MYC controls the 
generation of  self-renewing metastatic cancer cells. These 
results provide evidence that the conversion of  precancer-
ous to cancerous cells is determined by oncogenic RAS-
induced transcription factors, primarily MYC. In addition, 
a cooperative mechanism between mutant KRAS and PIK-
3CA has been recently shown, in part mediated by RAS/
p110α binding, as inactivating point mutations within the 
RAS-binding domain of  PIK3CA significantly ablates 
signalling pathways[37]. Indeed somatic cell knock-in of  
both KRASG12V and oncogenic PIK3CA mutations in hu-
man breast epithelial cells results in cooperative activation 
of  the PI3K and MAPK pathways in vitro, and leads to 
tumour formation in immunocompromised mice. Xeno-
grafts from double knock-in cells retain single copies of  
mutant KRAS and PIK3CA, suggesting that tumour for-
mation does not require increased copy number of  either 
oncogene. More importantly PDK1 seems to play a key 
role in this cooperativity, since PDK1-dependent activa-
tion of  the downstream effector p90RSK is increased by 
the combined presence of  mutant KRAS and PIK3CA. 
Finally, PDK1 has been recently found significantly over-
expressed in the high-grade intraductal papillary mucinous 
neoplasms (IPMN) vs low-grade IPMN and in pancreatic 
and intestinal-type of  IPMN vs gastric-type of  IPMN[38]. 
These data suggest that PDK1 may play a role in develop-
ment of  IPMN invasive cancer.
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MIR-375, AN ADDITIONAL LINK 
BETWEEN KRAS AND PDK1
MicroRNAs (miRNAs) modulate the expression levels 
of  mRNAs and proteins and can contribute to cancer 
initiation and progression[39]. In addition to their intracel-
lular function, miRNAs are released from cells and shed 
into the circulation. Increasing interest has been recently 
focused on the role of  miRNAs in pancreatic cancer ma-
lignant progression[40]. It has been reported that changes 
in miRNAs expression patterns during progression of  
normal tissues to invasive pancreatic adenocarcinoma in 
the p48-Cre/LSL-KRASG12D mouse model mirrors the 
miRNAs changes observed in human pancreatic can-
cer tissues[41]. It was found that the expressions of  miR-
148a/b and miR-375 were decreased whereas the levels 
of  miR-10, miR-21, miR-100 and miR-155 were increased 
in invasive carcinoma compared to normal tissues in the 
mouse model. Similar data have been found in KRAS on-
cogene transgenic rats with PDAC[42]. Recently, miR-375 
has been found downregulated in different cancers includ-
ing pancreatic cancer, and suppresses key cancer functions 
by targeting several signalling molecules such as PDK1[43]. 
It is worth noting that RAS can up-regulate PDK1 ex-
pression. Indeed, it has been shown that RAS drives 
monocytic lineage commitment in granular monocyte 
bipotential cells by promoting the expression of  PDK1[44]. 
Interestingly, a recent study investigated the transcriptional 
regulation of  miR-375 validated target PDK1[45] in pancre-
atic carcinoma[46]. miR-375 was observed to be downregu-
lated in the tumour compared with non-tumour tissues 
from patients with pancreatic cancer[41]. As determined 
by a luciferase reporter assay, the ectopic expression of  
miR-375 was able to reduce the transcriptional activity of  
PDK1 and the expression of  endogenous PDK1 protein 
levels. Functional assays showed that miR-375 was able to 
inhibit proliferation and promote apoptosis of  pancreatic 
cancer cells[46]. Therefore, miRNA-375 appears to be a key 
regulator of  PDK1, suggesting that it may have a poten-
tial therapeutic role in the treatment of  pancreatic cancer. 
Furthermore, this evidence suggests that miR-375 may 
represent an additional link between KRAS and PDK1 
since KRAS-induced downregulation of  miR-375 results 
in increased PDK1 expression.
CONCLUSION
This review provides evidence for a role of  the KRAS/
PDK1 axis in pancreatic cancer. Given the fact that 
KRAS is considered an “undruggable” protein the iden-
tification of  downstream targets is of  value for the future 
development of  alternative pharmacological strategies to 
block KRAS-dependent signalling pathways. Highly selec-
tive PDK1 inhibitors are now available and combination 
strategies may achieve more effective blockade of  this 
axis. At AACR 2012, a study demonstrated that nanopar-
ticles delivery of  a novel AKT/PDK1 inhibitor inhibits 
pancreatic cancer tumour growth[47]. MicroRNAs may 
provide alternative strategies for intervention. For instance 
miR-375 that is downregulated in pancreatic cancer can be 
used as an alternative strategy to counteract the KRAS/
PDK1 axis. Interestingly, miR-375 has been found down-
regulated in multiple types of  cancer, and suppresses core 
hallmarks of  cancer by targeting several important onco-
genes such as Yes-associated protein 1 (YAP1), insulin-like 
growth factor 1 receptor (IGF1R) and PDK1[43]. These 
oncogenes might play a key role in pancreatic adenocar-
cinoma progression. For instance, YAP1 has been found 
overexpressed in pancreatic cancer tissues and might play 
an important role in pancreatic cancer growth[48]. More 
importantly, IGF1R is emerging as a novel promising new 
drug targets in pancreatic cancer therapy[49]. Therefore, 
the understanding of  the role of  the KRAS/PDK1 axis 
in pancreatic cancer might provide a number of  novel 
therapeutic opportunities for a cancer that urgently needs 
immediate response to counteract its grim reality.
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